New Additions to Drugs.com for 2015
The following 53 drugs were added to the Drugs.com database in 2015.
Zurampic
Dec 30, 2015 - Zurampic (lesinurad) is a URAT1 inhibitor indicated for the combination treatment of hyperuricemia associated with gout.
Uptravi
Dec 30, 2015 - Uptravi (selexipag) is an oral prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension.
Alecensa
Dec 15, 2015 - Alecensa (alectinib) is an oral anaplastic lymphoma kinase (ALK) inhibitor for the treatment of people with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Vistogard
Dec 14, 2015 - Vistogard (uridine triacetate) is a pyrimidine analog indicated for the emergency treatment of adults and children who receive an overdose of the cancer treatments fluorouracil or capecitabine.
Vonvendi
Dec 12, 2015 - Vonvendi [von Willebrand factor (recombinant)] is a recombinant von Willebrand factor
(VWF) indicated for on-demand treatment and control of bleeding episodes in adults
diagnosed with von Willebrand disease.
Empliciti
Dec 1, 2015 - Empliciti (elotuzumab) is a Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody indicated in combination with either lenalidomide or pomalidomide, and dexamethasone for the treatment of patients with multiple myeloma.
Ninlaro
Nov 20, 2015 - Ninlaro (ixazomib) is an oral proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Narcan
Nov 20, 2015 - Narcan Nasal Spray (naloxone) is an intranasal opioid antagonist formulation indicated for the emergency treatment of known or suspected opioid overdose.
Darzalex
Nov 20, 2015 - Darzalex (daratumumab) is a human anti-CD38 monoclonal antibody indicated to treat patients with multiple myeloma.
Tagrisso
Nov 15, 2015 - Tagrisso (osimertinib) is an oral kinase inhibitor that may be used to treat adults with non-small cell lung cancer (NSCLC) whose tumors have certain abnormal epidermal growth factor receptor (EGFR) gene(s). It may be used as adjuvant therapy to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery; as your first treatment when your lung cancer has spread to other parts of the body (metastasized); when your lung cancer has spread to other parts of the body (metastasized) and you have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working; or in combination with pemetrexed and platinum-based chemotherapy, as your first treatment when your lung cancer has spread to nearby tissues (locally advanced) or to other parts of the body (metastasized).
Cotellic
Nov 10, 2015 - Cotellic (cobimetinib) is a kinase inhibitor for use in combination with vemurafenib for the treatment of advanced melanoma with a BRAF V600E or V600K mutation.
Utibron Neohaler
Nov 8, 2015 - Utibron Neohaler (glycopyrrolate and indacaterol) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) fixed-dose combination for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Genvoya
Nov 5, 2015 - Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide or E/C/F/TAF) is an antiretroviral combination for the treatment of HIV infection.
Nucala
Nov 4, 2015 - Nucala (mepolizumab) is a prescription medicine indicated for the treatment of patients with severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps.
Seebri
Nov 4, 2015 - Seebri Neohaler (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Imlygic
Oct 28, 2015 - Imlygic (talimogene laherparepvec) is a genetically modified oncolytic viral therapy indicated for the local treatment of melanoma lesions in the skin and lymph nodes.
Belbuca
Oct 28, 2015 - Belbuca (buprenorphine) buccal film is a partial opioid agonist analgesic indicated for the management of chronic pain.
Strensiq
Oct 27, 2015 - Strensiq (asfotase alfa) is a tissue nonspecific alkaline phosphatase enzyme replacement therapy indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
Yondelis
Oct 27, 2015 - Yondelis (trabectedin) is a cytotoxic antitumor agent for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma, two common subtypes of soft tissue sarcoma.
Veltassa
Oct 21, 2015 - Veltassa (patiromer) is an oral potassium binder for the treatment of hyperkalemia.
Dyanavel XR
Oct 20, 2015 - Dyanavel XR (amphetamine) is an extended-release central nervous system (CNS) stimulant for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Aristada
Oct 6, 2015 - Aristada (aripiprazole lauroxil) is an extended-release injectable atypical antipsychotic with one-month, six-week, and two-month dosing options for the treatment of schizophrenia.
Ryzodeg 70/30
Sep 30, 2015 - Ryzodeg 70/30 (insulin degludec and insulin aspart) is a long-acting insulin analog and rapid-acting human insulin analog combination indicated to improve glycemic control in adults with diabetes mellitus.
Tresiba FlexTouch
Sep 30, 2015 - Tresiba (insulin degludec) is a long-acting basal insulin analogue indicated to improve glycemic control in patients with type 1 and 2 diabetes mellitus.
Lonsurf
Sep 29, 2015 - Lonsurf (trifluridine and tipiracil) is a nucleoside metabolic inhibitor and thymidine phosphorylase inhibitor combination indicated for the treatment of patients with metastatic colorectal cancer who are no longer responding to other therapies.
Varubi
Sep 2, 2015 - Varubi (rolapitant) is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for use in combination with other antiemetic agents for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.
Repatha
Aug 31, 2015 - Repatha (evolocumab) is a monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) indicated for the treatment of patients with heterozygous familial hypercholesterolemia; homozygous familial hypercholesterolemia; and to reduce the risk of heart attack and stroke in people with heart disease.
Synjardy
Aug 30, 2015 - Synjardy (empagliflozin and metformin hydrochloride) is a sodium glucose co-transporter-2 (SGLT2) inhibitor and biguanide combination for the treatment of adults with type 2 diabetes.
Addyi
Aug 19, 2015 - Addyi (flibanserin) is a non-hormonal, multifunctional serotonin agonist antagonist (MSAA) for the treatment of hypoactive sexual desire disorder in premenopausal women.
Daklinza
Jul 27, 2015 - Daklinza (daclatasvir) is an NS5A inhibitor indicated for use in combination with sofosbuvir for the treatment of chronic hepatitis C virus (HCV) genotype 1 and genotype 3 infection.
Praluent
Jul 27, 2015 - Praluent (alirocumab) is an injectable medicine that is given under your skin which may be used in adults with cardiovascular disease to reduce the risk of heart attack, stroke, and certain types of chest pain conditions (unstable angina); or to treat high blood cholesterol including HeFH; or to treat HoFH homozygous familial hypercholesterolemia in adults who require additional lowering of their LDL-C. Praluent may also be used in children 8 years and older with HeFH to reduce LDL-C, alongside dietary changes and other LDL-lowering treatments.
Odomzo
Jul 26, 2015 - Odomzo (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (BCC).
Technivie
Jul 26, 2015 - Technivie (ombitasvir, paritaprevir and ritonavir) is an NS5A inhibitor, NS3/4A protease inhibitor, and CYP3A inhibitor fixed-dose combination indicated for use in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection.
Rexulti
Jul 11, 2015 -
Entresto
Jul 7, 2015 - Entresto (sacubitril and valsartan) is a neprilysin inhibitor and angiotensin II receptor blocker combination indicated to reduce the risk of death and hospitalization in patients with
chronic heart failure.
Orkambi
Jul 2, 2015 - Orkambi (ivacaftor and lumacaftor) is a CFTR potentiator and CFTR corrector combination designed to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation in their CFTR gene.
Viberzi
May 27, 2015 - Viberzi (eluxadoline) is a mu-opioid receptor agonist indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Stiolto Respimat
May 27, 2015 - Stiolto Respimat (olodaterol and tiotropium bromide) is a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).
Kybella
Apr 29, 2015 - Kybella (deoxycholic acid) is a cytolytic drug indicated to improve the appearance of fullness associated with submental fat (double chin).
Corlanor
Apr 20, 2015 - Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated for the treatment of chronic heart failure.
Cresemba
Mar 9, 2015 - Cresemba (isavuconazonium) is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
Zarxio
Mar 8, 2015 - Zarxio (filgrastim-sndz) is a leukocyte growth factor biosimilar to the reference product Neupogen, indicated for the treatment of neutropenia associated with chemotherapy.
Farydak
Feb 24, 2015 - Farydak (panobinostat) is a histone deacetylase inhibitor for the combination treatment of multiple myeloma.
Lenvima
Feb 13, 2015 - Lenvima (lenvatinib) is a multiple receptor tyrosine kinase (RTK) inhibitor for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.
Ibrance
Feb 11, 2015 - Ibrance (palbociclib) is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for the combination treatment of ER+, HER2- metastatic breast cancer.
Glyxambi
Feb 10, 2015 - Glyxambi (empagliflozin and linagliptin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination for the treatment of adults with type 2 diabetes.
Evotaz
Feb 4, 2015 - Evotaz (atazanavir and cobicistat) is a once-daily fixed-dose combination of a protease inhibitor and a pharmacokinetic enhancer for the treatment of HIV-1 infection.
Prezcobix
Feb 1, 2015 - Prezcobix (darunavir and cobicistat) is a once-daily fixed-dose combination containing a protease inhibitor and a pharmacokinetic enhancer for the treatment of HIV-1 infection.
Natpara
Jan 26, 2015 - Natpara (parathyroid hormone) is recombinant human parathyroid hormone 1-84 indicated to control hypocalcemia in patients with hypoparathyroidism.
Prestalia
Jan 26, 2015 - Prestalia (amlodipine besylate and perindopril arginine) is a calcium channel blocker and long-acting angiotensin-converting enzyme (ACE) inhibitor combination for the treatment of hypertension.
Cosentyx
Jan 21, 2015 -
Xtoro
Jan 14, 2015 - Xtoro (finafloxacin otic suspension) is a fluoroquinolone antimicrobial for the treatment of acute otitis externa, commonly known as swimmer’s ear.
Savaysa
Jan 14, 2015 - Savaysa (edoxaban) is an oral, once-daily factor Xa inhibitor anticoagulant indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment of deep vein thrombosis, and pulmonary embolism.